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Abstract 
Background:  Beta-blockers are recommended in heart failure patients with reduced ejection 
fraction (HFrEF) and sinus rhythm, but prescription rates are consistently lower in older patients 
and women.     
Objectives:  We sought to determine the efficacy and tolerability of beta-blockers in a broad age-
range of adult women and men with HFrEF by pooling individual patient data (IPD) from 
placebo-controlled randomized trials. 
Methods:  The study was a prospectively designed IPD meta-analysis of patients aged 40-85 
years in sinus rhythm at baseline, with left-ventricular ejection fraction <0.45.  The primary 
outcome was all-cause mortality and major secondary outcome heart failure hospitalization.  
Analysis was by intention to treat using an adjusted one-stage Cox proportional hazards model.  
Registration: PROSPERO CRD42014010012; Clinicaltrials.gov NCT00832442. 
Results:  13,833 patients were included from 11 trials, with median age 64 years and 24% 
women.  Beta-blockers were effective in reducing mortality versus placebo across all ages: 
Quartile 1 (median age 50) hazard ratio (HR) 0.66 (95% CI 0.53 to 0.83); Quartile 2 (median 60) 
HR 0.71 (0.58 to 0.87); Quartile 3 (median 68) HR 0.65 (0.53 to 0.78); Quartile 4 (median 75) 
HR 0.77 (0.64 to 0.92).  There was no significant interaction when age was modelled 
continuously (p=0.10) and the absolute mortality reduction was 4.3% over a median follow-up of 
1.3 years (number needed to treat=23).  Heart failure hospitalization was significantly reduced by 
beta-blockers, although this effect was attenuated at older age (interaction p=0.05).  There was no 
evidence of an interaction between treatment effect and gender in any age group.  Drug 
discontinuation was similar regardless of treatment allocation, age or gender (14.4% beta-
blockers, 15.6% placebo). 
Conclusion:  Irrespective of age or gender, patients with HFrEF in sinus rhythm should receive 
beta-blockers to reduce the risk of death and hospitalization.  
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Introduction 
Beta blockers reduce morbidity and mortality in patients with heart failure (HF) and reduced left-
ventricular ejection fraction (LVEF), and are a cornerstone of modern evidence-based treatment.  
Current HF guidelines do not differentiate treatment on the basis of age or gender, although 
initiation and maintenance of therapy is suboptimal both in older people and women.(1-3)  With 
increasing age, the likelihood of being a woman and having a less marked reduction in LVEF are 
both greater.  This interaction, along with relatively low numbers of older patients in randomized 
controlled trials (RCTs), has created uncertainty about the optimum management of elderly 
patients with heart failure and reduced ejection fraction (HFrEF), both in women and men.  
Moreover, there are theoretical concerns about altered pharmacokinetics in older people that 
might affect the dosage required or the tolerability of therapy.(4, 5)  Although sub-group data and 
the results from SENIORS (Study of the Effects of Nebivolol Intervention on Outcomes and 
Rehospitalisation in Seniors with Heart Failure) suggest that the efficacy of beta-blockers is 
retained in older patients(6-8), low uptake and poor maintenance of therapy continue to be a 
clinical reality.   
 
The Beta-blockers in Heart Failure Collaborative Group was set up to combine individual patient 
data (IPD) from the major RCTs in HF and provide clear direction on clinically-relevant patient 
subsets where there is uncertainty about the balance of safety and efficacy of beta-blockers.(9, 
10)  IPD meta-analysis allows more robust examination of treatment effects in sub-groups and 
enables time-to-event analyses adjusted for baseline covariates, making it the “gold standard” for 
the appropriate pooling of original data.(11)  We recently demonstrated that morbidity and 
mortality are not improved by beta-blockers in patients with HFrEF and concomitant atrial 
fibrillation, in contrast to those in sinus rhythm who had substantial reductions in hospitalization 
and all-cause mortality.(12)   In this analysis, we explore the interactions of beta-blocker efficacy 
and tolerability with age and gender, utilizing the largest and most robust dataset of pooled 
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randomized trial data.  Our aim was to inform clinicians on the appropriate use of these important 
therapeutic agents for patients with HFrEF in sinus rhythm. 
 
Methods 
The Beta-blockers in Heart Failure Collaborative Group (BB-meta-HF) is a multinational effort, 
combining individual data from the major RCTs investigating the use of beta-blockers in HF.  
The group consists of the leading investigators of these trials and international experts, with the 
support of the four pharmaceutical companies that conducted the original trials (AstraZeneca, 
GlaxoSmithKline, Merck Serono and Menarini).  This report was prepared according to the 
Preferred Reporting Items for Systematic reviews and Meta-Analyses of individual participant 
data (PRISMA-IPD) guidelines(13) and prospectively registered with Clinicaltrials.gov 
(NCT0083244) and the PROSPERO database of systematic reviews (CRD42014010012).(10)  
Detailed rationale and methods have previously been published.(9, 12)   
 
Eligibility, search strategy and data collection 
Published or unpublished RCTs were identified through computer aided searches (e.g. Medline 
and Current Contents), scrutiny of reference lists of trials, trials registries, meeting abstracts, 
review articles as well as discussion with group members and pharmaceutical manufacturers.  
RCTs were included that reported mortality as a primary or part of a composite outcome 
comparing beta-blockers versus placebo.  Only unconfounded head-to-head trials were eligible, 
with recruitment of >300 patients and planned follow-up of >6 months to make the project 
technically feasible and clinically-relevant.  The search results, individual study demographics 
and a standardized data request form to obtain IPD from each trial have been published.(9)   
 
Eleven studies were included that account for 95.7% of eligible participants recruited in RCTs 
6 
based on a systematic literature review: the Australia/New Zealand Heart Failure Study 
(ANZ)(14), the Beta-Blocker Evaluation Survival Trial (BEST)(15), the Carvedilol Post-Infarct 
Survival Control in LV Dysfunction Study (CAPRICORN)(16), the Carvedilol Hibernating 
Reversible Ischaemia Trial: Marker of Success Study (CHRISTMAS)(17), the Cardiac 
Insufficiency Bisoprolol Study (CIBIS I)(18), the Cardiac Insufficiency Bisoprolol Study II 
(CIBIS-II)(19), the Carvedilol Prospective Randomized Cumulative Survival Study 
(COPERNICUS)(20), the Metoprolol in Idiopathic Dilated Cardiomyopathy Study (MDC)(21), 
the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-
HF)(22, 23), the SENIORS Study(8) and the U.S. Carvedilol Heart Failure Study (US-HF).(24)  
All included studies had low risk of bias, as determined using the Cochrane Collaborations Risk 
of Bias Tool.(25) 
Patient involvement:  We have insufficient evidence to comment on whether patients were 
actively involved in the design or management of these eleven trials. 
 
Data were extracted from original source files and additional follow-up mortality outcomes were 
available in seven studies.19-21, 25, 26, 28, 29  The primary outcome of this analysis was all-cause 
mortality, including all reported deaths from each component study.  Major secondary outcomes 
were all-cause mortality during the trial period, all reported CV deaths, HF and CV 
hospitalization, fatal and non-fatal myocardial infarction (MI), fatal and non-fatal stroke, and 
composites of mortality and hospitalization.  One smaller study (1.4% of patients) did not provide 
data on hospitalization or other adverse clinical events(21), however all studies contributed to the 
primary outcome (Figure 1).  Safety outcomes focused on discontinuation of study drug therapy 
due to adverse events (hypotension, bradycardia, HF-exacerbation, renal impairment and 
respiratory dysfunction).  We defined tolerability as the dose achieved as a percentage of 
maximum target dose, according to the particular beta-blocker and specific trial design. 
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Population 
Individual patient data were available on a total of 18,637 patients.  For this analysis, restriction 
to patients with HFrEF was pre-specified with an LVEF cut-off of <0.45, chosen to reflect the era 
in which these trials were undertaken, and the cardiac imaging distinction that separates patients 
with moderate and severe left ventricular dysfunction from those with mild or ‘intermediate’ 
reduction in LVEF.  Only those in sinus rhythm at baseline were evaluated in light of our prior 
findings regarding the lack of prognostic benefit of beta-blockers in patients with atrial 
fibrillation.(12)  To improve the robustness of the age analysis across the combined dataset, we 
also excluded the 4% of patients at the extremes of age (outside the age range of 40-85 years).  
One patient in the placebo arm was recorded as alive during study visits, but had a missing final 
follow-up date and was excluded from analysis.  Age was primarily assessed as a continuous 
variable, with pre-specified division into quartiles.  Gender was explored as a secondary 
interaction variable across the age quartiles. 
 
Statistical analysis 
Data are presented as percentages, or median and interquartile range (IQR; displayed as 25th to 
75th centiles).  Estimated glomerular filtration rate (GFR) was calculated using the Modification 
of Diet in Renal Disease (MDRD) formula, normalized to a body surface area of 1.73 m2.  All 
analyses followed the principle of intention to treat.  Outcomes were analysed using a stratified 
Cox proportional hazards regression model.(26)  This is a one-stage fixed effects approach and 
assumes that all trials are estimating a common treatment effect with baseline hazards that vary 
across studies.  Hazard ratios (HR) and 95% confidence intervals (CI) are presented, along with 
corresponding p-values.  We pre-specified adjustment in Cox models for age, gender, prior MI 
and baseline NYHA class (I/II vs. III/IV), LVEF, heart rate, systolic blood pressure, diuretic 
therapy and angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers 
(ARB).  Age was explored using numerous non-linear methods, including fractional polynomial 
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models, but the best fit was obtained with a linear relation.  The amount of missing data for 
`baseline characteristics was minimal (see legend for Table 1) and hence imputation was not 
required.  The final population size for the fully-adjusted Cox model for the primary outcome was 
13,670 (Figure 1).  Kaplan Meier plots are used to graph the data (pooling data from all trials).  
As the follow-up periods in individual studies varied, data were censored at 1200 days (3.3 years) 
from randomization.  Heterogeneity for the primary outcome was assessed using the chi-squared 
test and I2 statistic, with the estimate of heterogeneity taken from the inverse-variance fixed-
effects two-stage model.(27)   A range of predefined sensitivity analyses were performed, 
including alternative censor points, analysis of the entire age-range, different LVEF cut-offs, 
exclusion of specific studies, additional baseline adjustment and random effects modelling.(28)  
Exploratory analyses included a per-protocol assessment of patients who remained on study 
therapy throughout the trial.  All models demonstrated valid proportional hazards as determined 
by Schoenfeld residuals.(29)  Interactions were assessed in all models according to best 
practice.(30, 31)  A two-tailed p-value of 0.05 was considered statistically significant.  Analyses 
were performed on Stata Version 13.1 (StataCorp LP, Texas) and R Version 3.0.2 (R Core Team, 
Vienna). 
 
 
Results 
Age, gender and baseline characteristics 
A total of 13,833 HFrEF patients in sinus rhythm were included in the analysis.  The median age 
was 64 years (IQR 55-71).  Women accounted for 24% of patients overall (n=3,283) and were 
older than men (66 years [IQR 58-73] versus 63 [IQR 55-71]) (Supplementary Figure A).  The 
median duration of HF before enrolment was 3 years (IQR 1-6) and median LVEF 0.27 (IQR 
0.20-0.33).  Baseline demographics according to age quartile are presented in Table 1 and by 
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gender in Supplementary Table A. 
 
Primary outcome 
Overall 16% of patients died over a median follow-up period of 1.3 years (IQR 0.8-1.9).  As 
expected, all-cause mortality was higher in older patients, with relatively higher rates of death 
due to HF and non-CV causes than younger patients (Supplementary Table B).  Compared to 
men, women had lower absolute rates of all-cause mortality (14% versus 16%), but causes of 
death were similar (Supplementary Table C).   
 
Beta-blockers significantly reduced all-cause mortality compared to placebo (968 deaths/7,060 
[13.7%] versus 1,222/6,773 [18.0%]).  The relative risk reduction with beta-blockers was 24%, 
with an absolute risk reduction of 4.3% (number needed to treat, NNT=23).  The adjusted HR 
was 0.70, 95% CI 0.64 to 0.77, p<0.0001.  Figure 2 displays the primary age analysis, assessing 
the hazard of death for beta-blockers compared to placebo across the range of age, modelled as a 
continuous variable.  No statistical interaction with age was identified (interaction p-value=0.10).  
Table 2 displays the hazard ratio and Figure 3 the Kaplan-Meier plots for each age quartile, 
confirming efficacy for the primary outcome in all quartiles, including the oldest patients.  
Similar absolute risk reductions with beta-blockers were noted in all age quartiles 
(Supplementary Table D).  Beta-blockers were effective in both women and men, in the whole 
group and within specific age quartiles (Table 2 and Figure 4).  All sensitivity analysis for the 
primary outcome identified similar results to the main statistical model (Supplementary Table 
E).   
 
Secondary outcomes  
There was attenuation of the benefits of beta blockers on CV death by age (interaction p-value of 
0.04) but there remained a statistically significant reduction in events even in the oldest age group 
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(Table 3).  Similar findings were seen with HF hospitalization (Figure 3 and Supplementary 
Table D), CV hospitalization and composite clinical outcomes.  Fatal and non-fatal MI or stroke 
were not reduced with beta-blockers in the whole group, nor in any age quartile (Table 2).  For 
all of the secondary outcomes, the effect in women and men were similar, with no interaction 
identified according to gender (Table 2 and Figure 4). 
All-cause, CV and HF-related hospitalization data are detailed in Table 3, divided by age 
quartiles and gender.  Hospitalization rates increased with age and were similar in both genders.  
In the oldest quartile, patients had more than one hospitalization per year, with half of these 
admissions due to HF, and a median length of stay of 7 days in hospital. 
 
Tolerability of therapy 
There were similar rates of discontinuation due to adverse events in the placebo and beta-blocker 
arms across age quartiles and gender, although these increased slightly with age (Table 4).  
Overall, a numerically lower number of patients discontinued beta-blockers (14.4% versus 15.6% 
in placebo).  Specific causes of beta-blocker discontinuation according to age and gender are 
displayed in Supplementary Table F.  Small numbers of patients discontinued therapy due to 
hypotension (0.7-1.6%), bradycardia (0-3.5%), HF exacerbation (2.0-4.9%), renal impairment (0-
1.2%) and respiratory compromise (0.5-1.2%).  Discontinuation was similar across age and 
gender, apart from a small excess in HF exacerbation in the youngest quartile for women 
compared to men (5.4% versus 2.2%) and in bradycardia in the oldest men (3.5% versus 0.7% in 
the oldest women).  Beta-blocker dose did not differ across age and gender, with patients 
attaining 73% of the target dose at the interim study point (Supplementary Table G), compared 
to 84% achieving the corresponding dose of placebo. 
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Discussion 
Principal findings 
Using the near-totality of available data from RCTs of beta-blockers in patients with HFrEF and 
sinus rhythm, our analysis shows that there is no evidence of a clinically significant interaction 
with age or gender with respect to all-cause mortality.  We observed a significant benefit from 
beta-blockers in each age quartile, with absolute mortality reductions of about 4% in the youngest 
and oldest patients.  Similar results were observed for HF-related hospital admission, with 
significant reductions in each age quartile, albeit with minor attenuation of treatment effect in 
older patients.  Discontinuation of therapy was similar in patients randomized to beta-blockers or 
placebo, even in older patients, suggesting that beta-blocker ‘intolerance’ in clinical practice may 
reflect false attribution to intercurrent events or pre-conceptions about side-effects. 
 
Clinical context: Age 
Heart failure guidelines recommend beta-blockers for patients with HFrEF, but have not 
previously been able to exclude an interaction with age.(32, 33)  As a result, prescription of 
therapy and long-term continuation have been lower in older patients(34-36), presumably as 
clinicians trade off a perceived lower efficacy with other considerations such as potential adverse 
events and polypharmacy.  The proportion of patients in our analysis aged >70 years was 30%, 
which does not reflect the “real world” population of HFrEF.  In the three largest US HF 
registries (ADHERE, OPTIMIZE-HF and Get With The Guidelines), the average age of HFrEF 
patients was 70 years (SD 14, 14 and IQR 58-80 respectively; total of 101,066 patients).(37)  
Similarly, in the Swedish Heart Failure Registry of 21,864 HFrEF patients, the mean age was 72 
years (SD 12).(38)  This confirms that older patients are under-represented in HF RCTs, 
necessitating the pooling of data to provide information on treatment efficacy.  In this context, 
IPD provides the only robust method to adequately combine sub-group data.(39)  
12 
There are important demographic changes noted with advancing age.  Compared to the youngest 
quartile, older patients were more often women (31% to 18%), had more ischemic aetiology 
(81% to 54%), higher LVEF (0.29 to 0.25), higher systolic BP (130 to 120 mmHg), lower heart 
rate (77 to 82 beats per minute), reduced kidney function (55 to 73 mL/min) and received digoxin 
less frequently (44% to 62%).  These factors are known to affect prognosis in HF in different 
ways.  Age is the most powerful predictor of prognosis but is not itself a predictor of response to 
treatment.  The higher systolic BP, higher LVEF and lower heart rate observed in older patients 
are predictors of better prognosis, whilst chronic renal impairment is associated with poor 
prognosis.  The median length of pre-trial HF was 2 years in the lowest age quartile and 3 years 
in the other age quartiles suggesting that patients were entered into the trials at a similar time 
after initial diagnosis, irrespective of age.  Type of death also differed between age groups; Fifty 
percent of deaths in the youngest quartile are classified as “sudden” compared to 34% in the 
oldest quartile, whereas HF deaths accounted for 16% compared to 31% respectively.  Thus the 
heterogeneity in age in the trials also reflects heterogeneity in HF aetiology and comorbidity 
patterns.  The results of this IPD meta-analysis, showing the clear benefit of beta-blockers across 
all age groups in spite of this heterogeneity, is an important finding that cannot be predicted by 
analysing patient characteristics and outcomes in observational datasets or mechanistic studies.  
Our assessment confirms that irrespective of different patient factors associated with age, patients 
in sinus rhythm benefit from beta-blocker therapy, a novel and important finding that informs 
clinical practice and underpins the applicability of current clinical guidelines.(32, 33) 
 
In general, the effect of beta-blockers was consistent on the major secondary outcomes analysed.  
We did identify attenuated prevention of hospital admission by beta-blockers with age (p=0.05 
for first HF related and p=0.04 for first CV hospitalization).  However, adjusted hazard ratios 
remained significant across age quartiles and for all outcomes, apart from two secondary 
outcomes (first CV hospitalization and the composite of CV death or HF hospitalization).  
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Reassuringly, we did not identify differences in HF-related hospital admissions according to age 
or gender, and the length of hospital stay was similar in all patients, regardless of age or gender.   
 
Clinical context: Gender 
Baseline demographics show that women with HF entered into RCTs are older than men and 
differences such as higher systolic BP, higher LVEF and lower eGFR may simply reflect this age 
difference.  Women have a lower incidence of ischemic aetiology and prior MI, although similar 
HF prevalence compared to men.(40)  Prognosis has been shown to be better in women, however 
mortality rates are still 25% over 3 years.(41)  Previous sub-group data from RCTs have provided 
conflicting results about the efficacy of beta-blockers in women, including equal benefit (for 
example the MERIT-HF and CIBIS trials)(42, 43), enhanced mortality reduction compared to 
men (US Heart Failure trial)(24) and also no effectiveness in women (BEST trial).(44)  Our 
results confirm that there is no difference in beta-blocker efficacy in HFrEF according to gender.  
Cause of death in women and men showed identical proportions and patterns for sudden, HF and 
non-CV deaths, which further support the concordance for recommendation of beta-blockers.  
Thus, beta-blocker therapy should not be withheld from women with HFrEF, a practice that has 
been reported alongside fewer cardiology assessments and cardiac procedures.(45)  Women were 
under-represented in the clinical trials we analysed (24%), and this continues to be the case; for 
example in the recent large RCT of angiotensin-neprilysin inhibition versus enalapril in HFrEF, 
women accounted for only 22% of the patients recruited.(46)  There is a clear need to improve 
the enrolment of women in order to provide realistic expectations of their risk and benefit from 
treatment. 
Side effects and tolerability 
Importantly for all ages and both genders, we identified low rates of beta-blocker discontinuation 
due to adverse events and similar withdrawal rates to placebo.   Although beta-blockers are often 
associated with side effects, data from randomised trials consistently show no true difference 
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compared to placebo in dizziness, diarrhoea, elevated blood sugar or depression, and little or no 
increase in lethargy with modern generation beta-blockers.(47-49)  This information should 
reassure clinicians about the tolerability of beta-blockers in view of the prognostic benefit we 
have identified in women and the elderly of both genders.  Elderly patients were able to reach 
similar maximal dosage compared to younger HFrEF patients.   
 
Strengths and limitations of study 
It is plausible that the benefits of beta blockers are attenuated in the very elderly (e.g. >80 years) 
although the amount of information on these patients in existing RCTs is scarce.  Extrapolation 
from Figure 2 indicates that any attenuation of prognostic benefit with age is actually quite mild 
and the effect of beta-blockers in patients >80 years will still be associated with hazard ratios of 
around 0.8 (giving a worthwhile 20% proportional reduction in the average risk of death).  In the 
extreme elderly, it is worth noting that there are competing mortality risks.  Even with pooling of 
IPD from all large datasets, there are limitations to inference of treatment effects in subgroups.  
Examining treatment interactions by age shows significant treatment benefits in each quartile, but 
assessing interactions of age and gender will be limited by the size of the groups, number of 
events and inclusion criteria for the component studies.  For example, a lack of interaction may 
not provide full information on treatment effects in very elderly women due to the atypical 
elderly cohort included in the original trials.  We specifically included only patients with HFrEF 
in sinus rhythm at baseline.  Although sensitivity analyses including all patients showed a similar 
lack of age or gender interaction, direct extrapolation to patients with LVEF>0.45 cannot be 
made.  Similarly, we have previously reported on outcomes for beta-blockers in patients with 
concomitant HF and atrial fibrillation(12), and although these patients have poor prognosis(50), 
they are distinctly different to patients with HF in sinus rhythm and require specific 
management.(51)   
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There have been changes in risk factor profiles and treatment patterns since the component 
studies were completed (for example the use of cardiac resynchronization therapy), however, 
beta-blockers are still a vital component of optimal care in these patients(52), and may have a 
synergistic effect (for example with mineralocorticoid receptor antagonists).(53)  Finally, as with 
all meta-analytical techniques, we are limited by the data provided from the individual studies, 
with the inherent heterogeneity of patient populations.  The strength of our analysis was the use 
of IPD from high quality RCTs, with near-totality of available data and methodical data 
extraction from original datasets(9), resulting in improved quality of outcome data across trials. 
 
Conclusions and policy implications 
This analysis confirms that beta-blockers reduce mortality and HF-related hospitalization in 
HFrEF patients with sinus rhythm, irrespective of age or gender.  Absolute effect sizes for all-
cause mortality were similar across age quartiles with no significant interaction using an adjusted 
continuous hazard model.  In addition, the tolerability of beta-blockers was similar to placebo, 
reinforcing the use of beta-blockers in all HFrEF patients in sinus rhythm, and discouraging the 
practice of withholding such therapy in women or elderly patients.  
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Summary Box 
What is already known on this topic  
• Beta-blockers can reduce mortality and hospital admission in heart failure patients with 
reduced ejection fraction and sinus rhythm 
• Older patients and women frequently receive less evidence-based treatment, and often at 
lower dosage than demonstrated as effective in clinical trials 
 
What this study adds 
• Our study used individual patient data from all major randomised controlled trials comparing 
beta-blockers versus placebo in heart failure patients with reduced ejection fraction and sinus 
rhythm 
• In these patients, we found that beta-blockers reduce all-cause mortality and heart failure 
hospitalisation, regardless of age or gender, and that tolerability of therapy was the same with 
beta-blockers and placebo 
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Print Abstract 
 
Study question: 
Is the effectiveness and tolerability of beta-blockers in heart failure patients with reduced ejection 
fraction and sinus rhythm the same in older patients and women? 
 
Methods: 
This study is a prospectively designed, individual patient data meta-analysis of randomised 
controlled trials comparing beta-blockers with placebo.  We included heart failure patients with 
left-ventricular ejection fraction <0.45, aged 40-85 years in sinus rhythm (n=13,833).  The 
primary outcome was all-cause mortality, analysed using an intention to treat, adjusted, one-stage 
Cox proportional hazards model. 
 
Study answer and limitations: 
Beta-blockers reduced all-cause mortality compared to placebo in all age-groups and both 
genders, with an adjusted hazard ratio of 0.70 (95% CI 0.64 to 0.77), absolute risk reduction of 
4.3%, and number needed to treat of 23 to prevent one death.  There was no interaction of 
treatment effect with age (p=0.10), and women received the same benefit even in the oldest age 
quartile (interaction p=0.54).  Drug discontinuation was similar, irrespective of age or gender 
(overall 14.4% for beta-blockers and 15.6% for placebo).  We are limited to the patients 
originally recruited, but were able to obtain a near-totality of available data from high quality 
randomised controlled trials. 
 
What this study adds: 
Our study shows that heart failure patients with reduced ejection fraction and sinus rhythm should 
not be deprived of beta-blocker therapy, regardless of age or gender, and that all patients tolerate 
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therapy well with similar withdrawal rates compared to placebo. 
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Table 1: Baseline characteristics by age quartile 
Characteristic 
Quartile 1 
(youngest) 
n=3,458 
Quartile 2 
 
n=3,590 
Quartile 3 
 
n=3,327 
Quartile 4 
(oldest) 
n=3,458 
Age, median years (IQR) 50 (46-53) 60 (58-62) 68 (66-70) 75 (73-78) 
Women, n (%) 639 (18%) 764 (21%) 794 (24%) 1,086 (31%) 
Ischaemic HF aetiology, n (%) 1,856 (54%) 2,478 (69%) 2,544 (76%) 2,798 (81%) 
Prior myocardial infarction, n (%) 1,648 (48%) 2,158 (60%) 2,190 (66%) 2,287 (66%) 
Prior coronary revascularization, n (%) 592 (18%) 785 (24%) 769 (25%) 753 (23%) 
Diabetes Mellitus, n (%) 681 (21%) 892 (27%) 833 (27%) 897 (26%) 
Years with HF diagnosis, median (IQR) 2 (1-5) 3 (1-6) 3 (1-7) 3 (1-6) 
LVEF, median (IQR) 0.25 (0.20-0.32) 0.26 (0.20-0.32) 0.27 (0.21-0.32) 0.29 (0.22-0.34) 
NYHA class III/IV, n (%) 2,359(68%) 2,440 (68%) 2,285 (69%) 2,081 (61%) 
Systolic BP, median mmHg (IQR) 120 (110-130) 120 (110-136) 126 (113-140) 130 (115-142) 
Diastolic BP, median mmHg (IQR) 78 (70-84) 78 (70-83) 77 (70-80) 75 (69-80) 
Heart rate, median bpm (IQR) 82 (74-91) 80 (72-88) 78 (72-86) 77 (70-85) 
Body mass index, median kg/m2 (IQR) 28 (25-33) 27 (25-31) 27 (24-30) 26 (24-29) 
Estimated GFR, median mL/min (IQR) 73 (61-86) 66 (54-79) 59 (48-71) 55 (44-67) 
Any diuretic therapy, n (%) 2,896 (84%) 3,055 (85%) 2,859 (86%) 3,000 (87%) 
ACEi or ARB, n (%) 3,332 (96%) 3,410 (95%) 3,154 (95%) 3,207 (93%) 
Aldosterone antagonists, n (%) 255 (8%) 188 (6%) 256 (8%) 369 (11%) 
Digoxin, n (%) 2,090 (62%) 1,956 (56%) 1,652 (51%) 1,504 (44%) 
ACEi, Angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; GFR, 
glomerular filtration rate; HF, heart failure; IQR, interquartile range; LVEF, left-ventricular ejection fraction; 
NYHA, New York Heart Association functional class. 
Missing data (total across all quartiles): Prior myocardial infarction n=30; Prior coronary revascularization n=900; 
Diabetes Mellitus n=809; Years with HF diagnosis n=2817; Systolic BP n=59; Diastolic BP n=65; Heart rate n=8; 
Body mass index n=128; GFR n=662; NYHA n=73; Diuretics n=1; Aldosterone antagonists n=890; Digoxin n=348. 
 
 Table 2: Hazard ratios for primary and secondary outcomes according to age quartile 
Beta-blockers versus placebo / 
Outcome 
Age 
(continuous) 
interaction p-
value 
 
Quartile 1 
(youngest) 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
(oldest) 
HR, 95% CI 
Gender 
interaction 
p-value 
HR, 95% CI 
Gender 
interaction 
p-value 
HR, 95% CI 
Gender 
interaction 
p-value 
HR, 95% CI 
Gender 
interaction 
p-value 
All-cause mortality 
(primary outcome) 
0.10 0.66, 0.53 to 0.83 0.70 0.71, 0.58 to 0.87 0.66 0.65, 0.53 to 0.78 0.09 0.77, 0.64 to 0.92 0.54 
All-cause mortality 
(during study period only) 
0.08 0.62, 0.48 to 0.78 0.74 0.72, 0.58 to 0.88 0.80 0.64, 0.52 to 0.78 0.09 0.77, 0.64 to 0.93 0.40 
CV death 0.04 0.66, 0.52 to 0.84 0.46 0.70, 0.56 to 0.87 0.57 0.59, 0.47 to 0.73 0.07 0.81, 0.66 to 0.99 0.43 
First HF-related hospitalization 0.05 0.59, 0.4 to 0.74 0.64 0.65, 0.54 to 0.78 0.54 0.68, 0.56 to 0.83 0.86 0.78, 0.64 to 0.94 0.74 
First CV hospitalization 0.04 0.65, 0.55 to 0.77 0.38 0.78, 0.68 to 0.91 0.70 0.74, 0.64 to 0.87 0.99 0.92, 0.80 to 1.07 0.15 
Death or CV hospitalization 0.03 0.66, 0.57 to 0.77 0.64 0.78, 0.68 to 0.89 0.46 0.73, 0.64 to 0.84 0.91 0.87, 0.77 to 1.00 0.07 
CV death or HF hospitalization 0.03 0.66, 0.56 to 0.77 0.79 0.78, 0.68 to 0.89 0.52 0.72, 0.62 to 0.82 0.98 0.89, 0.78 to 1.02 0.08 
Fatal and non-fatal MI 0.10 0.66, 0.39 to 1.09 0.16 0.64, 0.43 to 0.98 0.46 0.73, 0.46 to 1.14 0.98 0.94, 0.63 to 1.42 0.50 
Fatal and non-fatal stroke 0.55 0.73, 0.34 to 1.56 0.66 1.21, 0.65 to 2.25 0.62 1.00, 0.55 to 1.84 0.96 1.11, 0.65 to 1.90 0.65 
Analysed using the one-stage Cox regression model, with studies as strata (censor 1200 days); adjusted for age, gender, MI, NYHA class (I/II vs. III/IV), LVEF, heart rate, 
systolic blood pressure and baseline ACEi/ARB and diuretic therapy.  Gender interaction p-values are given for treatment allocation and gender within each age quartile.  
Note the MDC trial only contributes to mortality outcomes.  CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; MI, myocardial infarction. 
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Table 3: Hospitalization 
Hospitalization type 
Quartile 1 
(youngest) 
Quartile 2 Quartile 3 
Quartile 4 
(oldest) 
All ages 
Women Men Women Men Women Men Women Men Women Men 
All-cause hospitalization 
          
  Percentage with 1 or more admission 39% 31% 35% 36% 39% 40% 40% 43% 39% 37% 
  Average number of admissions per patient 
0.94  
(range 0-18) 
0.67  
(range 0-18) 
0.78  
(range 0-14) 
0.76  
(range 0-22) 
0.79  
(range 0-11) 
0.79  
(range 0-17) 
0.68  
(range 0-12) 
0.85  
(range 0-26) 
0.78  
(range 0-18) 
0.76  
(range 0-26) 
  Annualized hospitalization rate per patient 0.67 /year 0.69 /year 0.85 /year 0.81 /year 0.87 /year 0.86 /year 1.05 /year 1.06 /year 0.85 /year 0.85 /year 
CV-hospitalization 
          
  Percentage with 1 or more admission 25% 20% 23% 25% 27% 27% 28% 30% 26% 25% 
  Average number of admissions per patient 
0.48  
(range 0-13) 
0.38  
(range 0-14) 
0.44  
(range 0-13) 
0.46  
(range 0-16) 
0.47  
(range 0-10) 
0.46  
(range 0-10) 
0.43  
(range 0-12) 
0.50  
(range 0-16) 
0.45  
(range 0-13) 
0.44  
(range 0-16) 
  Annualized hospitalization rate per patient 0.36 /year 0.38 /year 0.47 /year 0.45 /year 0.56 /year 0.57 /year 0.67 /year 0.67 /year 0.51 /year 0.51 /year 
  Average length of stay a 
6 days  
(IQR 3-9) 
6 days  
(IQR 3-10) 
6 days  
(IQR 3-9) 
6 days  
(IQR 3-12) 
7 days  
(IQR 3-11) 
6 days  
(IQR 4-11) 
7 days  
(IQR 3-11) 
6 days  
(IQR 3-12) 
6 days  
(IQR 3-11) 
6 days  
(IQR 3-11) 
HF-related hospitalization 
          
  Percentage with 1 or more admission 19% 13% 16% 17% 17% 17% 16% 19% 17% 16% 
  Average number of admissions per patient 
0.36  
(range 0-7) 
0.25  
(range 0-12) 
0.32  
(range 0-13) 
0.31  
(range 0-16) 
0.29  
(range 0-10) 
0.29  
(range 0-10) 
0.25  
(range 0-12) 
0.32  
(range 0-16) 
0.30  
(range 0-13) 
0.29  
(range 0-16) 
  Annualized hospitalization rate per patient 0.24 /year 0.27 /year 0.32 /year 0.30 /year 0.33 /year 0.35 /year 0.46 /year 0.45 /year 0.34 /year 0.34 /year 
  Average length of stay a 
6 days  
(IQR 3-10) 
6 days  
(IQR 4-11) 
7 days  
(IQR 4-10) 
7 days  
(IQR 4-13) 
7 days  
(IQR 4-12) 
7 days  
(IQR 4-12) 
7 days  
(IQR 4-12) 
6 days  
(IQR 4-11) 
7 days  
(IQR 4-11) 
7 days  
(IQR 4-12) 
a Based on the first five hospital admissions for a cardiovascular (CV)/heart failure (HF) cause.  Note the MDC trial does not contribute to hospitalization outcomes. 
 Table 4: Discontinuation of study therapy 
Discontinuation due to any adverse event Placebo Beta-blockers 
Quartile 1 
(youngest) 
Women: 51/300 (17.0%) 
Men: 192/1375 (14.0%) 
All: 243/1,675 (14.5%) 
Women: 47/335 (14.0%) 
Men: 167/1435 (11.6%) 
All: 214/1,770 (12.1%) 
Quartile 2 
Women: 53/366 (14.5%) 
Men: 201/1371 (14.7%) 
All: 254/1,737 (14.6%) 
Women: 51/394 (12.9%) 
Men: 183/1449 (12.6%) 
All: 234/1,843 (12.7%) 
Quartile 3 
Women: 59/383 (15.4%) 
Men: 205/1259 (16.3%) 
All: 264/1,642 (16.1%) 
Women: 59/411 (14.4%) 
Men: 186/1271 (14.6%) 
All: 245/1,682 (14.6%) 
Quartile 4 
(oldest) 
Women: 90/537 (16.8%) 
Men: 200/1165 (17.2%) 
All: 290/1,702 (17.0%) 
Women: 86/549 (15.7%) 
Men: 233/1207 (19.3%) 
All: 319/1,756 (18.2%) 
All ages 
Women: 253/1586 (16.0%) 
Men: 798/5170 (15.4%) 
All: 1,051/6,756 (15.6%) 
Women: 243/1689 (14.4%) 
Men: 769/5362 (14.3%) 
All: 1,012/7,051 (14.4%) 
 
 Figure Legends 
 
Figure 1:  Study flowchart 
Flow diagram for included and excluded participants.  *The MDC trial only contributes to 
mortality outcomes. 
 
Figure 2:  Beta-blockers versus placebo hazard model for all-cause mortality and age 
Hazard ratio for beta-blockers compared to placebo in HFrEF patients with sinus rhythm.  
Age modelled as a continuous variable, with quartile results superimposed. 
 
Figure 3:  Kaplan-Meier event curves according to age quartile 
All-cause mortality (primary outcome; top panel) and HF hospitalization (major secondary 
outcome; lower panel) for beta-blockers versus placebo by age quartile.  ARR, absolute risk 
reduction; NNT, number needed to treat.  
 
Figure 4:  Kaplan-Meier event curves according to gender 
All-cause mortality (primary outcome; left panel) and HF hospitalization (major secondary 
outcome; right panel) for beta-blockers versus placebo by gender.  ARR, absolute risk 
reduction; NNT, number needed to treat.  
